PREVIOUS
✖
Cardiac Drug Vymada
September 20 , 2025
15 hrs 0 min
20
0
- India has revoked the patent for Novartis’ cardiac drug Vymada under Section 3(d) of the Patents Act.
- The decision was based on a lack of novelty, inventive step, and therapeutic efficacy.
- Vymada, sold globally as Entresto (sacubitril + valsartan), recorded $7.8 billion in global sales last year.
Leave a Reply
Your Comment is awaiting moderation.